Ligelizumab
Ligelizumab (INN; development code QGE031) is a humanized IgG1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria.[1] It is an anti-IgE that binds to IGHE an acts as an immunomodulator.[2][3]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IGHE |
| Clinical data | |
| Other names | QGE031 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6534H10000N1716O2038S44 |
| Molar mass | 146612.49 g·mol−1 |
This drug was developed by Novartis Pharma AG. Research funded by Novartis Pharma[4] concluded that Ligelizumab was more effective in treating chronic spontaneous urticaria than omalizumab or placebo.[5]
References
- Novartis Pharma AG (29 October 2014). "Ligelizumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2). 2012.
- Kocatürk E, Maurer M, Metz M, Grattan C (2017-01-10). "Looking forward to new targeted treatments for chronic spontaneous urticaria". Clinical and Translational Allergy. 7: 1. doi:10.1186/s13601-016-0139-2. PMC 5223554. PMID 28078079.
- Clinical trial number NCT02477332 for "A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)" at ClinicalTrials.gov
- Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, et al. (October 2019). "Ligelizumab for Chronic Spontaneous Urticaria". The New England Journal of Medicine. 381 (14): 1321–1332. doi:10.1056/NEJMoa1900408. PMID 31577874.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.